PMID- 23866721
OWN - NLM
STAT- MEDLINE
DCOM- 20150312
LR  - 20220408
IS  - 1560-8115 (Print)
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Linking)
VI  - 21
IP  - 1
DP  - 2013 Jul 17
TI  - Surface modification of PLGA nanoparticles via human serum albumin conjugation 
      for controlled delivery of docetaxel.
PG  - 58
LID - 10.1186/2008-2231-21-58 [doi]
AB  - BACKGROUND: Poly lactic-co-glycolic acid (PLGA) based nanoparticles are 
      considered to be a promising drug carrier in tumor targeting but suffer from the 
      high level of opsonization by reticuloendothelial system due to their hydrophobic 
      structure. As a result surface modification of these nanoparticles has been 
      widely studied as an essential step in their development. Among various surface 
      modifications, human serum albumin (HSA) possesses advantages including small 
      size, hydrophilic surface and accumulation in leaky vasculature of tumors through 
      passive targeting and a probable active transport into tumor tissues. METHODS: 
      PLGA nanoparticles of docetaxel were prepared by emulsification evaporation 
      method and were surface conjugated with human serum albumin. Fourier transform 
      infrared spectrum was used to confirm the conjugation reaction where nuclear 
      magnetic resonance was utilized for conjugation ratio determination. In addition, 
      transmission electron microscopy showed two different contrast media in 
      conjugated nanoparticles. Furthermore, cytotoxicity of free docetaxel, 
      unconjugated and conjugated PLGA nanoparticles was studied in HepG2 cells. 
      RESULTS: Size, zeta potential and drug loading of PLGA nanoparticles were about 
      199 nm, -11.07 mV, and 4%, respectively where size, zeta potential and drug 
      loading of conjugated nanoparticles were found to be 204 nm, -5.6 mV and 3.6% 
      respectively. Conjugated nanoparticles represented a three-phasic release pattern 
      with a 20% burst effect for docetaxel on the first day. Cytotoxicity experiment 
      showed that the IC50 of HSA conjugated PLGA nanoparticles (5.4 mug) was 
      significantly lower than both free docetaxel (20.2 mug) and unconjugated PLGA 
      nanoparticles (6.2 mug). CONCLUSION: In conclusion surface modification of PLGA 
      nanoparticles through HSA conjugation results in more cytotoxicity against tumor 
      cell lines compared with free docetaxel and unconjugated PLGA nanoparticles. 
      Albumin conjugated PLGA nanoparticles may represent a promising drug delivery 
      system in cancer therapy.
FAU - Manoochehri, Saeed
AU  - Manoochehri S
FAU - Darvishi, Behrad
AU  - Darvishi B
FAU - Kamalinia, Golnaz
AU  - Kamalinia G
FAU - Amini, Mohsen
AU  - Amini M
FAU - Fallah, Mahdieh
AU  - Fallah M
FAU - Ostad, Seyed Naser
AU  - Ostad SN
FAU - Atyabi, Fatemeh
AU  - Atyabi F
FAU - Dinarvand, Rassoul
AU  - Dinarvand R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130717
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 0 (Serum Albumin)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - Cell Survival/drug effects
MH  - Docetaxel
MH  - Hep G2 Cells
MH  - Humans
MH  - Lactic Acid/*chemistry
MH  - Nanoparticles/*chemistry
MH  - Particle Size
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Serum Albumin/*chemistry
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Taxoids/*pharmacology
PMC - PMC3720529
EDAT- 2013/07/23 06:00
MHDA- 2015/03/13 06:00
PMCR- 2013/07/17
CRDT- 2013/07/23 06:00
PHST- 2013/04/22 00:00 [received]
PHST- 2013/07/15 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2015/03/13 06:00 [medline]
PHST- 2013/07/17 00:00 [pmc-release]
AID - 2008-2231-21-58 [pii]
AID - 10.1186/2008-2231-21-58 [doi]
PST - epublish
SO  - Daru. 2013 Jul 17;21(1):58. doi: 10.1186/2008-2231-21-58.